Page 152 - Williams Hematology ( PDFDrive )

126 Part III: Epochal Hematology Chapter 8: Hematology during Pregnancy 127

46. Peyvandi F, Bidlingmaier C, Garagiola I. Management of pregnancy and delivery in 79. Rey E, Kahn SR, David M, et al: Thrombophilic disorders and fetal loss: A meta-analysis.
women with inherited bleeding disorders. Semin Fetal Neonatal Med 16:311, 2011. Lancet 361:901, 2003.
47. Briet E, Reisner HM, Blatt PM: Factor IX levels during pregnancy in a women with 80. Greer IA: Thrombophilia: Implications for pregnancy outcome. Thromb Res 109:73,
hemophilia B. Haemostasis 11:87, 1982. 2003.
48. Giangrande PL: Management of pregnancy in carriers of haemophilia. Haemophilia 81. Morrison ER, Miedzybrodzka ZH, Campbell DM, et al: Prothrombotic genotypes are
4:779, 1998. not associated with pre-eclampsia and gestational hypertension: Results from a large
49. Tsui NB, Kadir RA, Chan KC, et al: Noninvasive prenatal diagnosis of hemophilia by population-based study and systematic review. Thromb Haemost 87:779, 2002.
microfluidic digital PCR analysis of maternal plasma DNA. Blood 117:3684, 2011. 82. Gerhardt A, Scharf RE, Beckmann MW, et al: Prothrombin and factor V mutations in
50. Michiels JJ, Hamulyak K, Nieuwenhuis HK, et al: Acquired haemophilia A in women women with a history of thrombosis during pregnancy and the puerperium. N Engl J
postpartum: Management of bleeding episodes and natural history of the factor VIII Med 342:374, 2000.
inhibitor. Eur J Haematol 59:105, 1997. 83. Grandone E, Tomaiuolo M, Colaizzo D, et al: Role of thrombophilia in adverse obstetric
51. Solymoss S: Postpartum acquired factor VIII inhibitors: Results of a survey. Am J outcomes and their prevention using antithrombotic therapy. Semin Thromb Hemost
Hematol 59:1, 1998. 35:630, 2009.
52. Kobayashi T, Terao T, Kojima T, et al: Congenital factor XIII deficiency with treatment 84. Macklon NS, Greer IA, Bowman AW: An ultrasound study of gestational and pos-
of factor XIII concentrate and normal vaginal delivery. Gynecol Obstet Invest 29:235, tural changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynaecol
1990. 104:191, 1997.
53. Rodeghiero F, Castaman GC, Di Bona E, et al: Successful pregnancy in a woman with 85. Cockett FB, Thomas ML: The iliac compression syndrome. Br J Surg 52:816, 1965.
congenital factor XIII deficiency treated with substitutive therapy. Report of a second 86. Ginsberg JS, Brill-Edwards P, Burrows RF, et al: Venous thrombosis during pregnancy:
case. Blut 55:45, 1987. Leg and trimester of presentation. Thromb Haemost 67:519, 1992.
54. Burrows RF, Ray JG, Burrows EA: Bleeding risk and reproductive capacity among 87. Conard J, Horellou MH, Van Dreden P, et al: Thrombosis and pregnancy in congenital
patients with factor XIII deficiency: A case presentation and review of the literature. deficiencies in AT III, protein C or protein S: Study of 78 women. Thromb Haemost
Obstet Gynecol Surv 55:103, 2000. 63:319, 1990.
55. Anwar R, Miloszewski KJ: Factor XIII deficiency. Br J Haematol 107:468, 1999. 88. Battinelli EM, Marshall A, Connors JM: The role of thrombophilia in pregnancy.
56. Bornikova L, Peyvandi F, Allen G, et al: Fibrinogen replacement therapy for congenital Thrombosis 2013:516420, 2013.
fibrinogen deficiency. J Thromb Haemost 9:1687, 2011. 89. Robertson L, Wu O, Langhorne P, et al: Thrombophilia in pregnancy: A systematic
57. Burrows RF, Kelton JG: Fetal thrombocytopenia and its relation to maternal thrombo- review. Br J Haematol 132:171, 2006.
cytopenia. N Engl J Med 329:1463, 1993. 90. Benedetto C, Marozio L, Tavella AM, et al: Coagulation disorders in pregnancy:
58. George JN, Woolf SH, Raskob GE, et al: Idiopathic thrombocytopenic purpura: A prac- Acquired and inherited thrombophilias. Ann N Y Acad Sci 1205:106, 2010.
tice guideline developed by explicit methods for the American Society of Hematology. 91. Chabloz P, Reber G, Boehlen F, et al: TAFI antigen and D-dimer levels during normal
Blood 88:3, 1996. pregnancy and at delivery. Br J Haematol 115:150, 2001.
59. Kaplan C, Daffos F, Forestier F, et al: Fetal platelet counts in thrombocytopenic preg- 92. Paniccia R, Prisco D, Bandinelli B, et al: Plasma and serum levels of D-dimer and their
nancy. Lancet 336:979, 1990. correlations with other hemostatic parameters in pregnancy. Thromb Res 105:257, 2002.
60. Cromwell C, Tarantino M, Aledort LM: Safety of anti-D during pregnancy. Am J Hema- 93. Kobayashi T, Tokunaga N, Sugimura M, et al: Coagulation/fibrinolysis disorder in
tol 84:261, 2009. patients with severe preeclampsia. Semin Thromb Hemost 25:451, 1999.
61. Klink DT, van Elburg RM, Schreurs MW, van Well GT: Rituximab administration in 94. Brill-Edwards P, Ginsberg JS, Gent M, et al: Safety of withholding heparin in pregnant
third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immu- women with a history of venous thromboembolism. Recurrence of Clot in This Preg-
nol 2008:271363, 2008. nancy Study Group. N Engl J Med 343:1439, 2000.
62. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022291Orig1s011lbl.pdf, 95. Pabinger I, Grafenhofer H, Kyrle PA, et al: Temporary increase in the risk for recur-
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125268s141lbl.pdf rence during pregnancy in women with a history of venous thromboembolism. Blood
63. Patil AS, Dotters-Katz SK, Metjian AD, et al: Use of a thrombopoietin mimetic for 100:1060, 2002.
chronic immune thrombocytopenic purpura in pregnancy. Obstet Gynecol 122:483, 96. Ageno W, Crotti S, Turpie AG: The safety of antithrombotic therapy during pregnancy.
2013. Expert Opin Drug Saf 3:113, 2004.
64. van Veen JJ, Nokes TJ, Makris M: The risk of spinal haematoma following neuraxial 97. Bates SM, Greer IA, Middeldorp S, et al: Venous thromboembolism, thrombophilia
anaesthesia or lumbar puncture in thrombocytopeic individuals. Br J Haematol 148:15, antithrombotic therapy, and pregnancy. American College of Chest Physicians
2010. Evidence-Based Clinical Practice Guidelines (9th ed.). Chest 141(2 Suppl):e691S, 2012.
65. Valat AS, Caulier MT, Devos P, et al: Relationships between severe neonatal throm- 98. Bauer KA: Management of thrombophilia. J Thromb Haemost 1:1429, 2003.
bocytopenia and maternal characteristics in pregnancies associated with autoimmune 99. Bowles L, Cohen H: Inherited thrombophilias and anticoagulation in pregnancy. Best
thrombocytopenia. Br J Haematol 103:397, 1998. Pract Res Clin Obstet Gynaecol 17:471, 2003.
66. Martin JN Jr, Perry KG Jr, Blake PG, et al: Better maternal outcomes are achieved with 100. Ginsberg JS, Bates SM: Management of venous thromboembolism during pregnancy.
dexamethasone therapy for postpartum HELLP (hemolysis, elevated liver enzymes, J Thromb Haemost 1:1435, 2003.
and thrombocytopenia) syndrome. Am J Obstet Gynecol 177:1011, 1997. 101. Kearon C, Crowther M, Hirsh J: Management of patients with hereditary hypercoagula-
67. Woudstra DM, Chandra S, Hofmeyr GJ, Dowswell T: Corticosteroids for HELLP ble disorders. Annu Rev Med 51:169, 2000.
(hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy. Cochrane 102. Schafer AI, Levine MN, Konkle BA, et al: Thrombotic disorders: Diagnosis and treat-
Database Syst Rev (9):CD008148, 2010. ment. Hematology Am Soc Hematol Educ Program 520, 2003.
68. Katz L, Amorim M, Souza JP, et al: COHELLP: Collaborative randomized controlled 103. Clark SL, Porter TF, West FG: Coumarin derivatives and breast-feeding. Obstet Gynecol
trial on corticosteroids in HELLP syndrome. Reprod Health 10:28, 2013. 95:938, 2000.
69. Martin JN Jr, Blake PG, Perry KG Jr, et al: The natural history of HELLP syndrome: 104. Ward FT, Weiss RB: Lymphoma and pregnancy. Semin Oncol 16:397, 1989.
Patterns of disease progression and regression. Am J Obstet Gynecol 164:1500, 1991. 105. Doll DC, Ringenberg QS, Yarbro JW: Antineoplastic agents and pregnancy. Semin
70. Martin JN Jr, Files JC, Blake PG, et al: Postpartum plasma exchange for atypical Oncol 16:337, 1989.
preeclampsia-eclampsia as HELLP (hemolysis, elevated liver enzymes, and low plate- 106. Nisce LZ, Tome MA, He S, et al: Management of coexisting Hodgkin’s disease and preg-
lets) syndrome. Am J Obstet Gynecol 172:1107, 1995. nancy. Am J Clin Oncol 9:146, 1986.
71. Rouget JP, Goudemand J, Ducloux G, et al: [Circulating anticoagulant, recurrent 107. Woo SY, Fuller LM, Cundiff JH, et al: Radiotherapy during pregnancy for clinical stages
abortions and venous thrombosis: A new entity or a pre-lupus syndrome? 2 cases] [in IA-IIA Hodgkin’s disease. Int J Radiat Oncol Biol Phys 23:407, 1992.
French]. Ann Med Interne (Paris) 134:111, 1983. 108. Chen J, Lee RJ, Tsodikov A, et al: Does radiotherapy around the time of pregnancy for
72. Kutteh WH: Antiphospholipid antibodies and reproduction. J Reprod Immunol 35:151, Hodgkin’s disease modify the risk of breast cancer? Int J Radiat Oncol Biol Phys 58:1474,
1997. 2004.
73. Rai RS, Clifford K, Cohen H, et al: High prospective fetal loss rate in untreated preg- 109. Kal HB, Struikmans H. Radiotherapy during pregnancy: Fact and fiction. Lancet Oncol
nancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum 6:328, 2005.
Reprod 10:3301, 1995. 110. Gelb AB, van de Rijn M, Warnke RA, et al: Pregnancy-associated lymphomas. A clini-
74. Pengo V, Banzato A, Bison E, et al: What have we learned about antiphospholipid copathologic study. Cancer 78:304, 1996.
syndrome from patients and antiphospholipid carrier cohorts? Semin Thromb Hemost 111. Bobrow LG, Richards MA, Happerfield LC, et al: Breast lymphomas: A clinicopatho-
38:322, 2012. logic review. Hum Pathol 24:274, 1993.
75. Rai R, Cohen H, Dave M, et al: Randomised controlled trial of aspirin and aspirin plus 112. Brogi E, Harris NL: Lymphomas of the breast: Pathology and clinical behavior. Semin
heparin in pregnant women with recurrent miscarriage associated with phospholipid Oncol 26:357, 1999.
antibodies (or antiphospholipid antibodies). BMJ 314:253, 1997. 113. Horowitz NA, Benyamini N, Wohlfart K: Reproductive organ involvement in non
76. Brodsky RA: How I treat paroxysmal nocturnal hemoglobinuria. Blood 113:6522, 2009. -Hodgkin lymphoma during pregnancy: A systematic review. Lancet Oncol 14:e275,
77. Martinelli I, Taioli E, Cetin I, et al: Mutations in coagulation factors in women with 2013.
unexplained late fetal loss. N Engl J Med 343:1015, 2000. 114. Aviles A, Diaz-Maqueo JC, Talavera A, et al: Growth and development of children of
78. Ridker PM, Miletich JP, Buring JE, et al: Factor V Leiden mutation as a risk factor for mothers treated with chemotherapy during pregnancy: Current status of 43 children.
recurrent pregnancy loss. Ann Intern Med 128:1000, 1998. Am J Hematol 36:243, 1991.

Kaushansky_chapter 08_p0119-0128.indd 127 17/09/15 6:15 pm